investigated NSCLC patients receiving nivolumab immunotherapy and found that treatment responders had higher circulating level of effector, CD62Llow CD4+ T cells prior to PD-1 blockade that correlated with effector CD8+ T cell abundance, and these cells expressed surface markers indicative of TH1 phenotype (191). This evidence concerns the gene CD4 and non-small cell lung carcinoma.